DI CRISTO, VALENTINA
DI CRISTO, VALENTINA
Universita' degli Studi di MILANO
Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
2020 A. Antinori, M.V. Cossu, B. Menzaghi, G. Sterrantino, N. Squillace, V. Di Cristo, A. Cattelan, E. Foca, A. Castagna, G. Orofino, D. Valenti, G. D'Ettore, L. Aprea, S. Ferrara, M.E. Locatelli, G. Madeddu, E. Pontali, P. Scerbo, B. Rossetti, A. Uglietti, R. Termini, F. Rucci, A. Gori, D. Mancusi
Correction to: Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
2020 A. Antinori, M.V. Cossu, B. Menzaghi, G. Sterrantino, N. Squillace, V. Di Cristo, A. Cattelan, E. Focà, A. Castagna, G. Orofino, D. Valenti, G. D'Ettore, L. Aprea, S. Ferrara, M.E. Locatelli, G. Madeddu, E. Pontali, P. Scerbo, B. Rossetti, A. Uglietti, R. Termini, F. Rucci, A. Gori, D. Mancusi
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation
2020 V. Di Cristo, F. Adorni, R. Maserati, M. Annovazzi Lodi, G. Bruno, P. Maggi, A. Volpe, P. Vitiello, C. Abeli, S. Bonora, M. Ferrara, M.V. Cossu, M.L. Oreni, E. Colella, S. Rusconi
Gastrointestinal basidiobolomycosis: an emerging mycosis difficult to diagnose but curable: Case report and review of the literature
2019 M.D. Pezzani, V. Di Cristo, C. Parravicini, A. Sonzogni, C. Tonello, M. Franzetti, S. Sollima, M. Corbellino, M. Galli, L. Milazzo, S. Antinori
Orlistat: weight lost at cost of HIV rebound
2016 C. Gervasoni, D. Cattaneo, V. Di Cristo, S. Castoldi, E. Gervasi, E. Clementi, A. Riva
Abacavir-induced liver toxicity
2016 M.D. Pezzani, C. Resnati, V. Di Cristo, A. Riva, C. Gervasoni
Factors involved in continuance of atazanavir-based regimens : Results from a cohort of HIV1-positive patients
2016 A. Giacomelli, L. Oreni, M. Franzetti, V. Di Cristo, E. Colella, A.L. Ridolfo, M. Galli, S. Rusconi
Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
2014 A. Giacomelli, L. Oreni, M. Franzetti, V. Di Cristo, B. Vergani, M. Morosi, E. Colella, M. Galli, S. Rusconi
Atazanavir-induced severe episodes of kidney stones in an HIV-1-infected subject characterized by a CYP3A poor metabolizer phenotype
2014 S. Rusconi, R. Gagliardini, F.S. Falvella, D. Cattaneo, V. Di Cristo, A. De Luca, M. Fabbiani, E. Clementi, M. Galli, S. Di Giambenedetto
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients
2012 A. Giacomelli, M. Franzetti, B. Vergani, L. Oreni, M. Morosi, V. Di Cristo, E. Colella, O. Viganò, M. Galli, S. Rusconi